AINovo™ Biotech Inc.

Anvita Gupta is CEO of AINovo™ Biotech. Anvita has more than nine years of experience in artificial intelligence domains, including generative modeling, computer vision, and natural language processing for genomics, proteomics, and drug design for global academic labs at Stanford University, Harvard Medical School, and ETH Zurich.

In 2015, Anvita was invited to present her research on AI for drug discovery to President Obama at the White House, and presented the applications to the Ebola pandemic at the White House Ebola Innovators Conference hosted by USAID and OSTP.

Her research in generative modeling and protein design has been published in journals such as Wiley’s Molecular Informatics and Nature Machine Intelligence, and she has delivered talks at international conferences including ICML, ISMB, BIO, TEDx Redmond, and the ITC International Conclave.

Anvita received her M.Sc and B.Sc with honors in Computer Science from Stanford University specializing in Artificial Intelligence and Biocomputation.

Dr. Anup Kumar Gupta is CTO of AINovo™ Biotech. Dr. Gupta received his PhD and M.Sc in Chemical Engineering from the University of Calgary and his bachelors from IIT Kanpur. He has also earned an MBA from WP Carey School of Business at Arizona State University. Dr. Gupta has more than 35 years of experience in various domains including engineering, research, systems analysis, design and software development for Fortune 500 companies like Honeywell, Pearson Education, and Brown & Root. He also is a serial entrepreneur, with extensive experience in startup companies like 3P Software, Amba Solutions Inc, AINovo™ Biotech.

Prof (Dr) Ashok K Gupta is an internationally renowned Otorhinolaryngologist with over 35 years of experience in the field of ENT surgery. He has worked as Faculty at PGIMER and is currently Director of ENT & Head-Neck Surgery, Fortis Hospital, Mohali, Punjab. He was the organizing chairman of 1st National Robotic Assisted Head-Neck Workshop & Advanced ENT Surgical Update 2017 and has performed numerous head and neck robotic surgeriess in his career.

His expertise includes rhinology, skull base and head- neck surgery and undertakes all aspects of Endoscopic Sinus Surgery, Hernia Surgery, Voice Surgery, Neck Surgery. Dr Gupta received world-wide acclaim for his revolutionary research work "Stem cells in traumatic optic neuropathy". He has cured many patients from different parts of the country with total vision loss due to traumatic optic nerve injury using stem cells.

He is the member of the prestigious National Academy of Medical Sciences (NAMS). Prof Ashok Gupta was the first Indian to receive the Dr Joe V Desa-Memorial Oration Award at the 65th Annual Conference of the 'Association of Otolaryngologists of India-AOI'. This is the second oration award in a row bestowed on Prof Gupta. In addition, he has published over 113 papers in International Journals and 62 in National Journals.

Prof. Prince Sharma (FAMSc) , Dean Faculty of Science, Department of Microbiology, Panjab University, Chandigarh

Prof. Prince Sharma is working in the areas of Reverse Vaccinology, Antimicrobial Resistance, Industrial Enzymes and Biosensors for Microbial Diagnostics. He has one patent granted and two enzyme technologies transferred to industries (Cadilla, India and New England Biolabs,USA). Published 102 research papers, completed 13 research projects with DBT, DST, UGC, ICMR, DFS; and guided 25 PhD students. Got Glaxo Smith Kline Vaccine Travel Award for his work on Reverse Vaccinology in ECCMID conference in Amsterdam. His research paper on Reverse Vaccinology in SCIENTIFIC REPORTS was selected in top 100 papers of 2017. Defense Threat Reduction Agency, USA, sponsored him for European Biosafety Association Conference in Madrid, 2017. He is Associate Editor of Indian Journal of Microbiology ; Fellow of the Academy of Microbiological Sciences; President of Chandigarh Unit of Association of Microbiologists of India, Former Chairman of the Department of Microbiology, Panjab University. He is Sandia National Laboratory, USA (SNL)-Certified trainer in Panjab University for BioRisk Management and has conducted several training workshops in collaboration with SNL.

Prof.Neena Capalash, (Former Chairperson, Department of Biotechnology, Panjab University, Chandigarh)

Prof. Neena Capalash works in the area of microbial biotechnology and cancer epigenetics with focus on cervical cancer. Currently she is working on Acinetobacter baumannii, a nosocomial pathogen. Her lab’s works on attenuating its virulence by inhibiting quorum sensing, understanding the phenomenon of persister cells formation against antibiotics and exploring novel drug targets to control multiple drug resistant strains. She has published 87 research papers, 07 book Chapters and completed 8 research projects and guided 15 PhD students. She has to her credit the transfer of Technology of TspMI a highly stable, quick reaction Type II restriction endonuclease to New England Biolabs, USA She is also involved in capacity building for Biorisk management by conducting workshops every year since 2014 in collaboration with Sandia National Laboratories, USA. Defense Threat Reduction Agency, USA, sponsored her for European Biosafety Association Conference in Madrid, 2017.

Dr. Mahan currently serves as Chief Executive Officer of OB Pharmaceuticals, Inc. (Toronto, ON), a private late preclinical biopharmaceutical company focused on the development of novel molecules for the control of acquired seizures. Prior to this role, he has served as Chief Scientific Officer of Madeleine Pharmaceuticals, Inc. leading IND enabling R&D and CMC programs together with regulatory and clinical strategy for a cardiorenal biotherapeutic for heart failure. As former founder and president of BioConsult USA he provided professional consulting services in the innovation management of advanced biomedical technologies; having acted within and outside organizations to accelerate their mission and strategic vision. His specialties include technology evaluation, venture diligence, entrepreneur guidance and business strategy creation with a domestic and international track record in business alliance development.

His business expertise builds upon more than 20 years as an accomplished senior scientist in biomedical research including 12 years at the National Institutes of Mental Health (NIMH) and Neurological Disorders and Stroke (NINDS). His research has encompassed cellular and molecular biology, pharmacology, functional genomics, proteomics, and genetic engineering in the fields neuroscience and immunology with additional experience in biomedical device engineering principals and bioinformatics.

Dr. Mahan past roles have included Director of Innovation and Business Development for Children’s National Medical Center (Washington, DC), Executive Director of the Maryland Biotechnology Center, Director of Biosciences & Advanced Technologies for the Maryland Department of Commerce, Senior Strategy Advisor to the Office of the Governor (MD), and co-founder of TherExcell, Inc. (Vancouver, BC). Dr. Mahan holds a doctorate in Physiology and Pharmacology from the University of California, San Diego. He has more than 100 published articles and abstracts, and holds four US. patents with others pending. He has been an invited speaker globally on his scientific research and industry development in the biosciences.

Dr. Maecker is a Professor of Microbiology and Immunology and Director of the Human Immune Monitoring Center at Stanford University. His research focuses on measuring immune competence, as well as how specific cellular immune responses correlate with immune protection. Dr. Maecker received a BS in Microbiology from Purdue University and a PhD in Cancer Biology from Stanford University. He did postdoctoral work with Ronald and Shoshana Levy at Stanford, and was an Assistant Professor of Biology at Loyola University Chicago, as well as a Senior Scientist at BD Biosciences, San Jose, CA. View Stanford University Profile